Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) AI Stock Analysis

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

(HKEX:8329)

Select Model

Rating:60Neutral

Price Target:HKD 0.12▲(4.50% Upside)

Action:reiterated

Date:10/30/26

Overall score reflects solid technical momentum and a supportive balance sheet/FCF profile, offset by ongoing losses and margin compression that weaken financial performance and make the negative P/E a key risk despite the attractive dividend yield.

Positive Factors

Revenue reboundThe 19.3% TTM revenue rebound indicates renewed sales traction after weaker prior growth. If sustained, improving demand can support operating leverage, strengthen the company’s market position, and provide a larger base from which profitability may recover over the next several quarters.

Negative Factors

Persistent losses and margin compressionThe return to net losses, negative operating profit, and materially lower gross margin shows that revenue growth has not yet translated into durable earnings. Continued margin pressure could limit reinvestment capacity, weaken returns, and make the recent sales rebound less valuable to shareholders.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 164.25M
Dividend Yield: 4.84%
Average Volume (3M): 477.02K
Price to Earnings (P/E): -3.2
Beta (1Y): 0.08
Revenue Growth: -5.00%
EPS Growth: -976.92%
Country: Hong Kong
Employees: 1,321
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the pr...

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Financial Statement Overview

Summary

Mixed fundamentals: TTM revenue rebounded strongly (+19.3%) and cash generation is solid (positive operating cash flow and free cash flow), supported by low leverage (debt-to-equity ~0.15). However, profitability remains weak with net losses in 2025 and TTM, negative operating profit, and materially compressed gross margin versus 2022–2023.

Income Statement

41Neutral

Balance Sheet

70Positive

Cash Flow

63Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.12B	972.01M	1.04B	1.06B	986.69M	838.80M
Gross Profit	326.93M	287.22M	328.04M	439.24M	444.14M	368.13M
EBITDA	62.20M	53.77M	69.29M	69.89M	125.24M	73.97M
Net Income	-49.34M	-40.74M	25.01M	24.13M	54.35M	35.96M
Balance Sheet
Total Assets	1.07B	1.06B	1.40B	1.42B	1.45B	1.31B
Cash, Cash Equivalents and Short-Term Investments	212.22M	209.45M	283.42M	382.21M	350.10M	311.14M
Total Debt	96.37M	73.02M	105.43M	89.69M	92.69M	105.69M
Total Liabilities	359.20M	352.70M	371.99M	399.46M	442.93M	363.17M
Stockholders Equity	654.38M	647.73M	933.18M	908.17M	884.04M	829.70M
Cash Flow
Free Cash Flow	132.87M	124.95M	2.20M	38.32M	41.51M	-85.00M
Operating Cash Flow	144.90M	139.59M	24.41M	53.69M	61.22M	-69.92M
Investing Cash Flow	-14.64M	83.26M	-114.62M	60.90M	10.76M	-181.57M
Financing Cash Flow	-24.72M	-306.92M	1.43M	-32.48M	-9.02M	66.75M

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Technical Analysis

Technical Analysis SentimentPositive

Last Price0.11

Price Trends

50DMA0.10Positive

100DMA0.10Positive

200DMA0.12Negative

Market Momentum

MACD0.00Negative

RSI61.04Neutral

STOCH71.51Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8329, the sentiment is Positive. The current price of 0.11 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and below the 200-day MA of 0.12, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 61.04 is Neutral, neither overbought nor oversold. The STOCH value of 71.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8329.

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:8329 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1061	73Outperform	HKD 1.19B	4.45	10.70%	5.74%	-0.74%	-15.21%
HK:8049	73Outperform	HKD 1.48B	4.49	15.91%	―	0.20%	24.13%
HK:8329	60Neutral	HKD 186.26M	-3.21	-7.58%	4.84%	-5.00%	-976.92%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:6185	51Neutral	HKD 13.23B	632.61	0.60%	―	36.09%	―
HK:2627	49Neutral	HKD 11.54B	-37.70	-101.49%	―	―	―
HK:0013	45Neutral	HKD 18.13B	143.19	1.43%	―	-8.55%	-96.20%

* Healthcare Sector Average

Performance Comparison

HK:8329 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8329	Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H	0.11	-0.03	-23.45%
HK:0013	HUTCHMED (China) Limited	20.78	-2.98	-12.54%
HK:1061	Essex Bio-Technology	2.09	-2.09	-49.95%
HK:8049	Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H	2.65	0.69	35.55%
HK:6185	CanSino Biologics, Inc. Class H	25.78	-21.42	-45.38%
HK:2627	Ab&B Bio-Tech CO., LTD. JS Class H	29.32	-10.52	-26.41%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H AI Stock Analysis